Epstein-Barr virus is a ubiquitous human herpesvirus infecting greater than 95% of the adult population and is associated with numerous human cancers. One recent report identified an association between a suppressor of cell migration Nm23-H1 and one of the essential EBV latent antigens, EBNA3C. This was a critical finding as it was the first discovery of a tumor virus antigen been involved in regulation of cell migration. EBNA3C was shown to reverse the inhibitory effects of Nm23-H1 and mediates the translocation of Nm23-H1 to the nucleus. In this proposal we will investigate the association of these molecules in EBV infected cells and further characterize the interaction to determine specific motifs that may be important for interaction of Nm23-H1. We will identify and characterize cellular and viral proteins that associate with Nm23-H1 in complex with EBNA3C as well as other critical EBNA protein including EBNA1. We will also screen for cellular genes that may be regulated by Nm23-H1 using microarray analyses and determine the transcription profiles in the presence and absence of EBNA3C/EBNA1. Specific cellular genes will be selected that are known to be involved in cell migration. We will determine if Nm23-H1 and the EBV EBNA protein can alter the transcriptional activities of these known cellular genes. Further analyses will be completed on the promoters to determine the specific binding sites of these cellular factors through mutagenesis and biochemical analyses that will provide a readout of the effects on transcription and cell migration. Cellular molecules that also associate with Nm23-H1 will also be investigated to determine the functional consequences of the associations. These studies will elucidate a mechanism by which EBV and possible tumor viruses can affect cell migration in infected tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA108461-05
Application #
7439091
Study Section
Special Emphasis Panel (ZRG1-AARR-B (03))
Program Officer
Daschner, Phillip J
Project Start
2004-07-01
Project End
2011-04-30
Budget Start
2008-05-01
Budget End
2011-04-30
Support Year
5
Fiscal Year
2008
Total Cost
$332,863
Indirect Cost
Name
University of Pennsylvania
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Verma, Subhash C; Cai, Qiliang; Kreider, Edward et al. (2013) Comprehensive analysis of LANA interacting proteins essential for viral genome tethering and persistence. PLoS One 8:e74662
Cai, Qiliang; Xiao, Bingyi; Si, Huaxin et al. (2012) Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog 8:e1002566
Cai, Qiliang; Guo, Yi; Xiao, Bingyi et al. (2011) Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog 7:e1002418
Saha, Abhik; Robertson, Erle S (2011) Functional modulation of the metastatic suppressor Nm23-H1 by oncogenic viruses. FEBS Lett 585:3174-84
Gao, Jianming; Cai, Qiliang; Lu, Jie et al. (2011) Upregulation of cellular Bcl-2 by the KSHV encoded RTA promotes virion production. PLoS One 6:e23892
Cai, Qiliang; Verma, Suhbash C; Kumar, Pankaj et al. (2010) Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS One 5:e9720
Choudhuri, Tathagata; Murakami, Masanao; Kaul, Rajeev et al. (2010) Nm23-H1 can induce cell cycle arrest and apoptosis in B cells. Cancer Biol Ther 9:1065-78
Xiao, Bingyi; Verma, Subhash C; Cai, Qiliang et al. (2010) Bub1 and CENP-F can contribute to Kaposi's sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J Virol 84:9718-32
Cai, Qiliang; Robertson, Erle S (2010) Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS One 5:
Lan, Ke; Murakami, Masanao; Bajaj, Bharat et al. (2009) Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther 8:2136-43

Showing the most recent 10 out of 22 publications